Back to Search Start Over

Bioavailability of the Tablet Dosage Form of a Benzimidazole Derivative Possessing Antiplatelet Activity.

Bioavailability of the Tablet Dosage Form of a Benzimidazole Derivative Possessing Antiplatelet Activity.

Authors :
Spasov, A. A.
Kucheryavenko, A. F.
Gaidukova, K. A.
Sirotenko, V. S.
Smirnova, L. A.
Ryabukha, A. F.
Kuznetsov, K. A.
Velikopol'skaya, M. V.
Source :
Pharmaceutical Chemistry Journal; Nov2022, Vol. 56 Issue 8, p1024-1026, 3p
Publication Year :
2022

Abstract

The bioavailability of the tablet dosage form of pharmaceutical substance RU-891, i.e., 9-(3,4-dihydroxyphenacyl)-2,3-dihydroimidazo[1,2-a]benzimidazole hydrobromide, was investigated. The main pharmacokinetic parameters were determined. The relative bioavailability index was estimated at 93.98%. No evidence of drug accumulation from an RU-891 270-mg tablet dosage form was detected in rabbits upon threefold administration at a dose of 23 mg/kg. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
0091150X
Volume :
56
Issue :
8
Database :
Complementary Index
Journal :
Pharmaceutical Chemistry Journal
Publication Type :
Academic Journal
Accession number :
160372592
Full Text :
https://doi.org/10.1007/s11094-022-02746-4